|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.14 DKK | -3.00% |
|
-6.78% | -7.00% |
| 18/05 | Lundbeck's Asedebart Secures Orphan Drug Designation in Japan | MT |
| 18/05 | Lundbeck granted Orphan Drug Designation in Japan for asedebart | FW |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Pharmaceuticals Wholesale
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 621.29Cr | |||||
| 9.14TCr | |||||
| 4.57TCr | |||||
| 2.35TCr | |||||
| 825.49Cr | |||||
| 806.59Cr |
- Stock Market
- Equities
- HLUN B Stock
- Charts H. Lundbeck A/S
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition